Medtronic Achieves Record Revenue Growth as Stock Faces Mixed Analyst Ratings

Medtronic Achieves Record Revenue Growth as Stock Faces Mixed Analyst Ratings

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has recently reported its financial results for the fourth quarter and full fiscal year 2026, showcasing significant growth and strategic advancements.

Fourth Quarter and Full Year Fiscal 2026 Results

In the fourth quarter, Medtronic achieved revenue of $9.8 billion, marking a 9.9% increase as reported and a 6.6% organic growth. This performance exceeded the company’s implied guidance by 90 basis points. The GAAP diluted earnings per share (EPS) stood at $0.96, while the non-GAAP diluted EPS was $1.55, both surpassing expectations. Notably, the Cardiac Ablation Solutions segment experienced a remarkable 78% revenue increase globally, including a 124% growth in the U.S., capturing an additional 8 points of U.S. market share. The Cardiovascular segment grew by 10.1%, driven by mid-single-digit growth in Cardiac Rhythm Management, with mid-teens growth in Micra™ and a strong OmniaSecure™ U.S. launch.

For the full fiscal year 2026, Medtronic delivered its highest annual revenue growth in a decade, underscoring the company’s disciplined execution and robust portfolio. These results position Medtronic for continued momentum into fiscal year 2027.

Dividend Announcement

Consistent with its commitment to returning value to shareholders, Medtronic announced a quarterly cash dividend of $0.71 per share for the third quarter of fiscal year 2026. This declaration continues the company’s impressive track record as an S&P 500 Dividend Aristocrat, having increased its annual dividend for 48 consecutive years.

Stock Performance

As of July 17, 2026, Medtronic’s stock (MDT) is trading at $83.20, reflecting a slight decrease of 0.38% from the previous close. The stock’s performance is influenced by various factors, including recent financial results, strategic initiatives, and broader market conditions.

Analyst Perspectives

Analysts have provided mixed perspectives on Medtronic’s stock. BTIG analyst Ryan Zimmerman raised the firm’s price target to $91 from $90, maintaining a Buy rating, citing the company’s strong performance and growth prospects. Conversely, TD Cowen lowered its price target to $100 from $119, also maintaining a Buy rating, reflecting cautious optimism. These differing viewpoints highlight the complexities investors consider when evaluating Medtronic’s stock.

Conclusion

Medtronic’s recent financial performance demonstrates robust growth and strategic execution. The company’s consistent dividend increases and strong market presence underscore its commitment to delivering value to shareholders. As Medtronic continues to navigate the evolving healthcare landscape, investors will closely monitor its strategic initiatives and market performance.